• RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »

  • 340B Orphan Drug Rule Invalidated

    U.S. District Judge Rudolph Contreras has ruled that HRSA lacks regulatory authority to promulgate regulations expanding access to 340B discounts for so-called Orphan Drugs.   Rules that went into effect in October of 2013 implemented provisions of the Affordable Care Act that excluded orphan drugs from 340B pricing.  In the rules HRSA interpreted the exception… Read more »